Latest news with #Non-AlcoholicSteatohepatitis
Time of India
3 days ago
- Health
- Time of India
PGI researchers give new hope for treatment of severe liver disease
Lucknow: Advanced scientific research conducted by scientists at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) has shown a new way to treat Non-Alcoholic Steatohepatitis (NASH) – a severe but common liver disease. Tired of too many ads? go ad free now The research, led by Rohit A Sinha, a scientist and associate professor in the endocrinology department, along with his team comprising Sana Raza and Pratima Gupta, proved that a naturally occurring hormone called dehydroepiandrosterone (DHEA) can help in checking liver damage caused by NASH by removing harmful fat from liver cells, reducing inflammation, and preventing liver damage. A Union health ministry document notes that NASH is the severest form of Non-Alcoholic Fatty Liver Disease (NAFLD). Terming it as "a silent epidemic", the document noted that NAFLD's community prevalence ranges from 9% to 32%, depending on age, gender, area of residence, and socioeconomic status. This means that up to three people out of 10 could have fatty liver or a related disease. What raises concerns is that 20% of people with NAFLD develop NASH. "DHEA is a parent hormone that acts as a precursor to sex hormones in humans. While scanning several case studies of NASH patients, we noted that the level of DHEA in them was on the lower side. Keeping this as the base, we proposed to study the impact of increasing this hormone in NASH patients with a significant extent of fibrosis – a symptom of NASH," said Sinha, adding that the study was published in the journal 'Molecular and Cellular Endocrinology'. "We began with animal studies. In the mouse model, we fed the experimental group with a NASH-inducing diet. When the condition was confirmed in them, we injected DHEA. The outcome showed that the severity of liver damage in 80% of the sample decreased by about 60%," he said. The results paved the way for a cellular study in which the researchers worked upon lab-grown human liver cells. "Here too, in the experimental group, we loaded the cells with excessive fat to create a NASH-like condition. Thereafter, we introduced DHEA and found that the fat percentage decreased by up to 80%," said Sinha. "The result has been heartening. We now look forward to clinical trials for hormone replacement therapy," he said.
Yahoo
13-05-2025
- Business
- Yahoo
Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight Report, 2025 - Featuring Analysis of Inventiva Pharma, Cirius Therapeutics, Terns Pharmaceuticals, HighTide Biopharma, Eli Lilly and Company, and More
Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025" clinical trials has been added to report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Non-Alcoholic Steatohepatitis (NASH) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this HighlightsThe companies and academics are working to assess challenges and seek opportunities that could influence Non-Alcoholic Steatohepatitis (NASH) R&D. The therapies under development are focused on novel approaches to treat/improve Non-Alcoholic Steatohepatitis (NASH).Non-Alcoholic Steatohepatitis (NASH) Emerging Drugs ChaptersThis segment of the Non-Alcoholic Steatohepatitis (NASH) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press Steatohepatitis (NASH) Emerging Drugs Lanifibranor: Inventiva PharmaLanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARa and PPARd, and a partial activation of PPAR?. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to Lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Cirius TherapeuticsMSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of Terns PharmaceuticalsTERN-501 is a THR-ß agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-ß compared to other THR-ß agonists in development. Agonism of THR-ß increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-ß stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-ß than for THR-ß activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of 1801: HighTide BiopharmaThe company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).LY3849891: Eli Lilly and CompanyLY3849891 is being developed by Eli Lilly and Company and is evaluated in participants with nonalcoholic fatty liver disease who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Steatohepatitis (NASH): Therapeutic AssessmentThis segment of the report provides insights about the different Non-Alcoholic Steatohepatitis (NASH) drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Non-Alcoholic Steatohepatitis (NASH) There are approx. 80+ key companies which are developing the therapies for Non-Alcoholic Steatohepatitis (NASH). The companies which have their Non-Alcoholic Steatohepatitis (NASH) drug candidates in the most advanced stage, i.e. Phase III include, Cirius Therapeutics and Inventiva Pharma. Phases The report covers around 80+ products under different phases of clinical development, like: Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of: Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of AdministrationNon-Alcoholic Steatohepatitis (NASH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as: Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types, such as: Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product TypeDrugs have been categorized under various product types like Mono, Combination and Mono/ Development ActivitiesThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Alcoholic Steatohepatitis (NASH) therapeutic drugs key players involved in developing key ActivitiesThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Alcoholic Steatohepatitis (NASH) drugs. Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Non-Alcoholic Steatohepatitis (NASH) drugs? How many Non-Alcoholic Steatohepatitis (NASH) drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non-Alcoholic Steatohepatitis (NASH) therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Non-Alcoholic Steatohepatitis (NASH) and their status? What are the key designations that have been granted to the emerging drugs? Key Players Guangdong Raynovent Biotech Dr. Falk Pharma GmbH Enyo Pharma Viking Therapeutics Eli Lilly and Company Sagimet Biosciences Terns Sinew Pharma Madrigal Pharmaceuticals Hepion Pharmaceuticals Poxel SA Pfizer CytoDyn Altimmune Oramed, Ltd. PharmaKing Can-Fite Biopharma Cirius Therapeutics Key Products ZSP1601 ZED1227 EPY 651 VK2809 LY3849891 TVB-2640 TERN-501 SNP-630 Resmetirom Rencofilstat PXL065 PF-06865571 leronlimab Pemvidutide ORMD-0801 Oltipraz Namodenoson MSDC-0602K For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
India.com
30-04-2025
- Health
- India.com
Is Sedentary Lifestyle Linked To Fatty Liver Disease? Expert Advice On MASLD
In modern society, a sedentary lifestyle has become increasingly prevalent, characterized by prolonged periods of sitting, minimal physical activity, and high screen time. While the detrimental effects of this lifestyle on cardiovascular health and metabolic disorders like diabetes are well-established, its significant association with Metabolic dysfunction associated Steatotic Liver Disease (MASLD) is gaining increasing recognition within the medical community. Spokesperson Dr Srujan Kumar Dasyam, Consultant Medical Gastroenterologist, Hepatologist & Therapeutic Endoscopist, KIMS Hospital Hyderabad shares tips with us on how to improve liver health: MASLD is a condition where excess fat accumulates in the liver of individuals who consume little to no alcohol. It's a spectrum of conditions, ranging from simple steatosis (fatty liver) to Non-Alcoholic Steatohepatitis (NASH), which involves inflammation and liver cell damage, potentially leading to fibrosis, end stage liver disease called Cirhhosis and even liver cancer/Hepatocellular carcinoma. Several possible connections elucidate how a sedentary lifestyle contributes to the development and progression of MASLD. Firstly, reduced physical activity leads to decreased energy expenditure. This can result in a positive energy balance, where excess calories are stored as fat, including in the liver. As highlighted by Johns Hopkins Medicine, obesity and excess body weight, particularly abdominal fat, are significant risk factors for MASLD. Secondly, a sedentary lifestyle is often associated with metabolic dysfunction. According to the Mayo Clinic, insulin resistance, a condition where the body's cells become less responsive to insulin, is strongly linked to MASLD. Lack of physical activity can exacerbate insulin resistance, leading to increased fat storage in the liver. Furthermore, sedentary behavior can negatively impact lipid metabolism, resulting in elevated levels of triglycerides and low-density lipoprotein (LDL) cholesterol, further contributing to hepatic steatosis. Moreover, chronic low-grade inflammation, often seen in individuals with sedentary habits and obesity, may play a crucial role in the progression from simple fatty liver to NASH. Adipose tissue, especially visceral fat that accumulates with inactivity, releases pro-inflammatory cytokines, which can promote liver inflammation and damage. Advice for Patients to Improve Liver Health: For patients with or at risk of MASLD, adopting a more active lifestyle is paramount. Here are some practical steps: * Incorporate Regular Physical Activity: Aim for at least 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking, jogging, or cycling. Even shorter bursts of activity throughout the day can be beneficial. Johns Hopkins Medicine emphasizes that lifestyle changes, including weight loss through diet and exercise, are crucial for managing MASLD. * Reduce Sedentary Time: Break up long periods of sitting with short walks or standing breaks every 30 minutes. Consider incorporating standing desks or active workstations. * Adopt a Healthy Diet: Focus on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Limit the intake of saturated and trans fats, processed foods, and sugary drinks. * Gradual Weight Loss: If overweight or obese, aim for gradual and sustainable weight loss, typically 1-2 pounds per week. Losing even 5-10% of body weight can significantly improve liver health. * Manage Underlying Conditions: Effectively manage conditions like type 2 diabetes, high blood pressure, and high cholesterol, as these are closely linked to NAFLD. By understanding the detrimental impact of a sedentary lifestyle on liver health and implementing these lifestyle adjustments, patients can take proactive steps towards improving their liver health and reducing the risk of NAFLD progression. Regular consultation with healthcare professionals is essential for personalized advice and monitoring.
Los Angeles Times
15-04-2025
- Health
- Los Angeles Times
Understanding Non-Alcoholic Steatohepatitis (NASH): Causes, Diagnosis & Treatment
Non-Alcoholic Steatohepatitis, or NASH, is a type of Non-Alcoholic Fatty Liver Disease (NAFLD). Unlike alcohol related liver damage, NASH is caused by too much fat accumulating in the liver which causes inflammation and harm to liver cells [1]. Over time this can lead to scarring (fibrosis), cirrhosis or even liver cancer – specifically hepatocellular carcinoma (HCC). Table of Contents In NASH, fat builds up in liver cells and they balloon. The causes of fat in the liver are not fully understood and while certain health conditions may contribute to NAFLD, some people develop NAFLD with no known risk factors. When this balloon-ization persists it damages the liver's ability to filter out bad stuff and support digestion. Because NASH develops silently people may not notice anything at first. Some may just feel tired or a mild ache on the right side of the upper abdomen. Others may find out they have NASH after a routine blood test shows elevated liver enzymes and they get checked out [1], [2]. This particular form of liver disease is different from others such as Hepatitis B, C, D, E, and NAFLD. NASH is a complex condition with multiple contributing factors. Obesity is a major risk factor, as excess body weight can lead to fat accumulation in the liver, setting the stage for NASH. Insulin resistance, often preceding type 2 diabetes, is another significant factor, as it can promote fat storage in the liver. Metabolic syndrome, which includes high blood pressure, high cholesterol, and insulin resistance, increases NASH risk. Women with polycystic ovary syndrome (PCOS) face a higher risk due to hormonal imbalances and insulin resistance. A family history of liver disease or NASH also raises the likelihood of developing the condition. Other key risk factors include high blood pressure and high LDL cholesterol, both of which can contribute to liver damage and NASH progression. Understanding these risk factors is crucial for early detection and prevention of this serious liver disease. Doctors diagnose NASH by confirming fat in the liver, ruling out high alcohol use and other liver diseases (like viral hepatitis). Recently the term 'metabolic dysfunction associated steatohepatitis' (MASH) has been introduced to better reflect the underlying metabolic issues. Key tests include:* Treating Non-Alcoholic Steatohepatitis (NASH) involves a combination of lifestyle changes and medical interventions aimed at reducing liver fat, inflammation and scarring. Key strategies include: Overall, managing NASH involves a comprehensive approach that includes adopting a healthy lifestyle, monitoring by healthcare professionals and considering medications when appropriate. This multi-faceted strategy is essential to prevent complications such as liver cancer, cardiovascular diseases and the need for a liver transplant. NASH can lead to severe complications such as liver cancer and the need for a liver transplant. Chronic liver damage increases the risk of liver cells becoming cancerous. In cases of extensive liver damage a transplant may be required to replace the failing liver. NASH also increases the risk of cardiovascular disease (heart attacks and strokes) due to its association with metabolic syndrome. Type 2 diabetes and kidney disease are also potential complications as insulin resistance and advanced liver damage affects kidney function. Managing NASH is key to preventing these serious health issues. Since NASH can progress silently doctors often schedule regular checkups and scans every 6-24 months. These may include: Scarring in the liver (fibrosis) can progress to cirrhosis and limit liver functions. People with cirrhosis can experience fluid retention, confusion due to toxin buildup and increased risk of HCC [1]. Those with NAFLD are at higher risk of heart disease which is the leading cause of death in this condition [4]. Managing NASH often means managing overall health including blood pressure, cholesterol and blood sugar. NASH is a serious liver disease with fat accumulation, inflammation and potential scarring. Early detection can be difficult as the condition can progress without symptoms. However blood tests and imaging scans can help doctors identify problems before they get worse. The best defense is a balanced diet, regular exercise and moderate weight loss. Meds can support that in certain situations and ongoing studies are exploring new treatments [3]. With regular monitoring and healthier habits many can protect their liver and reduce risk of complications. [1] Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., Otsuka, M., Tamaki, N., Kogiso, T., Miwa, H., Chayama, K., Enomoto, N., Shimosegawa, T., Takehara, T., & Koike, K. (2021). Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatology research : the official journal of the Japan Society of Hepatology, 51(10), 1013–1025. [2] Long, M. T., Noureddin, M., & Lim, J. K. (2022). AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology, 163(3), 764–774.e1. [3] Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., Taub, R., & Moussa, S. E. (2019). Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 394(10213), 2012–2024. [4] Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., Otsuka, M., Tamaki, N., Kogiso, T., Miwa, H., Chayama, K., Enomoto, N., Shimosegawa, T., Takehara, T., & Koike, K. (2021). Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Journal of gastroenterology, 56(11), 951–963.
